FIELD: medical equipment.
SUBSTANCE: system for determining an immune status or an immune cycle of a subject comprises a sampling component for obtaining physiological data from an individual associated with changes in the immune system, relating to immune system markers, a biomarker and/or body temperature data for a period of time of two or more days. Data storage component is designed to store physiological data received from the subject. Processing component for analyzing physiological data collected over a certain period of time, is intended for determining on this basis the immune status or periodicity of the immune cycle and the immune cycle of the individual and extrapolating the obtained immune cycle to determine immune status and/or immune cycle in future. Output component for outputting the immune status or periodicity of the immune cycle, and the subject's immune and/or future status or the subject's immune cycle. What is disclosed is a system for improving the physiological response to the session, a method for determining the immune status, method of optimizing a physiological response of a subject to occupancy and a method of improving a physiological response of a subject to occupation.
EFFECT: technical result is enabling the possibility of determining the immune status of an individual when monitoring loads.
27 cl, 8 dwg, 8 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR IMPROVING COGNITIVE FUNCTIONS DISORDERS AND A COMPUTER-READABLE MEDIUM | 2019 |
|
RU2712704C1 |
BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | 2014 |
|
RU2820869C1 |
BIOMARKERS AND METHODS OF TREATING ASSOCIATED WITH PD-1 AND PD-L1 CONDITIONS | 2014 |
|
RU2701378C2 |
METHOD FOR SELF-DIAGNOSING EARLY DISORDERS OF COGNITIVE FUNCTIONS AND A DATA MEDIUM | 2019 |
|
RU2712574C1 |
CHROMOGRANIN A AS MARKER OF BLADDER CANCER | 2017 |
|
RU2785737C2 |
BIOMARKERS OF METHOTREXATE-INDUCED IMMUNE TOLERANCE | 2018 |
|
RU2795201C2 |
MR-proADM AS MARKER FOR EXTRACELLULAR VOLUME STATUS OF SUBJECT | 2016 |
|
RU2778457C2 |
FECAL MICROBIOTA COMPOSITION FOR USE IN REDUCING TREATMENT-INDUCED INFLAMMATION | 2019 |
|
RU2816462C2 |
PHYSIOLOGICALLY ACTIVE SUBSTANCE SRFM AS BLOOD BIOMARKER FOR DIAGNOSING HUMAN NEURODEGENERATIVE DISORDERS AND DISEASES | 2023 |
|
RU2822604C1 |
CD40L ANTAGONIST AND METHODS OF ITS USE | 2019 |
|
RU2812919C2 |
Authors
Dates
2020-04-23—Published
2015-12-03—Filed